论文部分内容阅读
目的观察立普妥(阿托法他汀)治疗冠心病患者C-反应蛋白的变化,以了解立普妥的非调脂作用。方法70例冠心病患者随机分成常规治疗组(未服任何调脂药),立普妥治疗组(服立普妥10 mg/d),测定治疗前后C-反应蛋白(CRP)及胆固醇(TC),甘油三酯(TG),低密度脂蛋白(LDL-C)的变化。结果治疗组治疗前后CRP及血脂各组成分差异均有统计学意义。结论在冠心病治疗中,使用立普妥治疗,除可明显降低血脂水平外,还可短期内安全有效地降低血浆CRP水平,可有效减少冠心病事件发生,改善预后。
Objective To observe the changes of C-reactive protein in patients with coronary heart disease treated with Lipitor (atorvastatin) in order to understand the non-lipid-lowering effect of Lipitor. Methods Seventy patients with coronary heart disease were randomly divided into routine treatment group (without any lipid-lowering drugs) and Lipitor treatment group (service-endoprost 10 mg / d). The levels of C-reactive protein ), Triglyceride (TG), low density lipoprotein (LDL-C) changes. Results Before and after treatment in the treatment group, the differences of CRP and blood lipid among the groups were statistically significant. Conclusion In the treatment of coronary heart disease, the use of Lipitor treatment, in addition to significantly lower blood lipid levels, but also short-term safe and effective reduction of plasma CRP levels, can effectively reduce the incidence of coronary heart disease and improve prognosis.